Health Outcomes of Youth in Clinical Pediatric Weight Management Programs in POWER - 24/04/19
on behalf of the
POWER Work Group∗
Abstract |
Objective |
To describe treatment outcomes of children and adolescents enrolled in the Pediatric Obesity Weight Evaluation Registry, a consortium of multicomponent pediatric weight management programs in the US.
Study design |
This multicenter prospective observational cohort study, established in 2013, includes youth (2-18 years of age) with obesity enrolled from 31 Pediatric Obesity Weight Evaluation Registry (POWER) sites over a 2-year period and followed up to 12 months. Weight status was evaluated by the percentage of the 95th percentile for body mass index (%BMIp95). Associations of weight status outcomes with patient characteristics and program exposure were analyzed with multivariable mixed effects modeling.
Results |
We included 6454 children and adolescents (median age, 11 years; IQR, 9-14 years; 53% white, 32% Hispanic; 73% with severe obesity) who were enrolled in POWER. Median changes in %BMIp95 for this cohort were −1.88 (IQR, −5.8 to 1.4), −2.50 (IQR, −7.4 to 1.8), −2.86 (IQR, −8.7 to 1.9), at 4-6, 7-9, and 10-12 of months follow-up, respectively (all P < .05). Older age (≥12 years), greater severity of obesity, and Hispanic race/ethnicity were associated with better improvement in %BMIp95. A 5-percentage point decrease in %BMIp95 was associated with improvement in cardiometabolic risk factors.
Conclusions |
Overall, treatment in pediatric weight management programs is associated with a modest median decrease in BMI as measured by change in %BMIp95. Further studies are needed to confirm these findings, as well as to identify additional strategies to enhance the effectiveness of these multicomponent interventions for youth with severe obesity.
Trial registration |
ClinicalTrials.gov: NCT02121132.
Le texte complet de cet article est disponible en PDF.Abbreviations : ALT, BMI, %BMIp95, ΔBMIp95, BMIz, DSCF, HbA1c, HDL-C, POWER, PWM, TG
Plan
Funded by site enrollment fees for their participation in the Pediatric Obesity Weight Evaluation Registry. A.K. receives research support (drug/placebo) from AstraZeneca Pharmaceuticals and serves as a consultant for Novo Nordisk, Orexigen, and Vivus Pharmaceuticals, but does not accept personal or professional income for these activities. The other authors declare no conflicts of interest. |
|
The other authors declare no conflicts of interest. |
|
Portions of this study were presented at the Pediatric Academic Societies annual meeting, May 6-9, 2017, San Francisco, California. |
Vol 208
P. 57 - mai 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?